Working with communities to close gaps in heart disease and cancer care

Working with communities to close gaps in heart disease and cancer care
metzgma4

/by

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
arcticnovartis

  • Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1
  • 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1
  • Fabhalta granted priority review by FDA for traditional approval

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN).

/by

Novartis withdraws EMA application for adding new indication for Pluvicto®

Novartis withdraws EMA application for adding new indication for Pluvicto®
weberfr8

/by

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis

– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases
   
– Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression
   
– Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience
  

/by

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis

– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases
   
– Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression
   
– Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience
  

/by

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
arcticnovartis

– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases
   
– Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression
   
– Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience
  

/by

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
arcticnovartis

  • New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented

  • Long-term Cosentyx® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasis

  • Additional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab 

/by

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis

  • Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer 
  • The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerability
/by

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
arcticnovartis

  • Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer 
  • The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Kα mutations in breast cancer while sparing wild-type PI3Kα, thus reducing unwanted side effects and improving tolerability
/by